New depression pill shows promise in phase 3 trial
NCT ID NCT06963021
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tests whether adding NBI-1065845 to standard antidepressants can better reduce depression symptoms in adults with major depressive disorder. About 200 participants who haven't fully responded to their current antidepressant will receive either the study drug or a placebo for 8 weeks. The main goal is to see if the drug improves mood and daily functioning more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGChino, California, 91710, United States
-
Neurocrine Clinical Site
RECRUITINGLos Angeles, California, 90025, United States
-
Neurocrine Clinical Site
RECRUITINGStanford, California, 94305, United States
-
Neurocrine Clinical Site
RECRUITINGAurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITINGCromwell, Connecticut, 06416, United States
-
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITINGFarmington, Connecticut, 06030, United States
-
Neurocrine Clinical Site
RECRUITINGMaitland, Florida, 32751, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33136, United States
-
Neurocrine Clinical Site
WITHDRAWNTampa, Florida, 33613, United States
-
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITINGGaithersburg, Maryland, 20877, United States
-
Neurocrine Clinical Site
RECRUITINGCedarhurst, New York, 11516, United States
-
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITINGNew York, New York, 10029, United States
-
Neurocrine Clinical Site
RECRUITINGNew York, New York, 10128, United States
-
Neurocrine Clinical Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITINGAlken, 3570, Belgium
-
Neurocrine Clinical Site
RECRUITINGBruges, 8310, Belgium
-
Neurocrine Clinical Site
RECRUITINGMechelen, 2800, Belgium
-
Neurocrine Clinical Site
RECRUITINGToronto, Ontario, M5B 1W8, Canada
-
Neurocrine Clinical Site
RECRUITINGKuopio, 70110, Finland
-
Neurocrine Clinical Site
RECRUITINGOulu, 90100, Finland
-
Neurocrine Clinical Site
RECRUITINGTampere, 33210, Finland
-
Neurocrine Clinical Site
RECRUITINGBudapest, 1036, Hungary
-
Neurocrine Clinical Site
RECRUITINGBudapest, 1083, Hungary
-
Neurocrine Clinical Site
RECRUITINGGyöngyös, 3200, Hungary
-
Neurocrine Clinical Site
RECRUITINGJelgava, LV-3008, Latvia
-
Neurocrine Clinical Site
RECRUITINGLiepāja, LV-3401, Latvia
-
Neurocrine Clinical Site
RECRUITINGSigulda, LV-2150, Latvia
-
Neurocrine Clinical Site
RECRUITINGManchester, M8 5RB, United Kingdom
-
Neurocrine Clinical Site
RECRUITINGSheffield, S5 7JT, United Kingdom
-
Neurocrine Clinical Site
RECRUITINGSouthampton, SO30 3JB, United Kingdom
Conditions
Explore the condition pages connected to this study.